PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 400 shares, a decrease of 63.6% from the November 30th total of 1,100 shares. Based on an average daily volume of 2,700 shares, the short-interest ratio is currently 0.1 days.
PureTech Health Stock Performance
Shares of PureTech Health stock remained flat at $32.77 during trading on Wednesday. 12 shares of the stock were exchanged, compared to its average volume of 1,771. The stock's 50-day moving average is $31.01 and its two-hundred day moving average is $27.44. PureTech Health has a one year low of $18.15 and a one year high of $43.57.
Get
PureTech Health alerts:
Institutional Trading of PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. lifted its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. 0.25% of the stock is currently owned by institutional investors and hedge funds.
About PureTech Health
(Get Rating)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
Featured Stories
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Yum! Brands Looks Tasty in 2023
- Why Did Immutep Ltd Stock Soar Recently?
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
